Prions: Protein Aggregation and Infectious Diseases - Physiological ...
Prions: Protein Aggregation and Infectious Diseases - Physiological ...
Prions: Protein Aggregation and Infectious Diseases - Physiological ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
1142 ADRIANO AGUZZI AND ANNA MARIA CALELLA<br />
79. Bruce ME, McBride PA, Farquhar CF. Precise targeting of the<br />
pathology of the sialoglycoprotein, PrP, vacuolar degeneration in<br />
mouse scrapie. Neurosci Lett 102: 1–6, 1989.<br />
80. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D,<br />
Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S,<br />
Fraser H, Bostock CJ. Transmissions to mice indicate that “new<br />
variant” CJD is caused by the BSE agent. Nature 389: 498–501,<br />
1997.<br />
81. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L,<br />
Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. Inherent<br />
toxicity of aggregates implies a common mechanism for protein<br />
misfolding diseases. Nature 416: 507–511, 2002.<br />
82. Buchanan CR, Preece MA, Milner RD. Mortality, neoplasia, <strong>and</strong><br />
Creutzfeldt-Jakob disease in patients treated with human pituitary<br />
growth hormone in the United Kingdom. BMJ 302: 824–828, 1991.<br />
83. Büeler H, Raeber A, Sailer A, Fischer M, Aguzzi A, Weissmann<br />
C. High prion <strong>and</strong> PrPSc levels but delayed onset of disease<br />
in scrapie-inoculated mice heterozygous for a disrupted PrP gene.<br />
Mol Med 1: 19–30, 1994.<br />
84. Büeler HR, Aguzzi A, Sailer A, Greiner RA, Autenried P,<br />
Aguet M, Weissmann C. Mice devoid of PrP are resistant to<br />
scrapie. Cell 73: 1339–1347, 1993.<br />
85. Büeler HR, Fischer M, Lang Y, Bluethmann H, Lipp HP, De-<br />
Armond SJ, Prusiner SB, Aguet M, Weissmann C. Normal<br />
development <strong>and</strong> behaviour of mice lacking the neuronal cellsurface<br />
PrP protein. Nature 356: 577–582, 1992.<br />
86. Burwinkel M, Schwarz A, Riemer C, Schultz J, Van L<strong>and</strong>eghem<br />
F, Baier M. Rapid disease development in scrapie-infected<br />
mice deficient for CD40 lig<strong>and</strong>. EMBO Rep 5:527–531, 2004.<br />
87. Buschmann A, Biacabe AG, Ziegler U, Bencsik A, Madec JY,<br />
Erhardt G, Luhken G, Baron T, Groschup MH. Atypical scrapie<br />
cases in Germany <strong>and</strong> France are identified by discrepant reaction<br />
patterns in BSE rapid tests. J Virol Methods 117: 27–36, 2004.<br />
88. Calzolai L, Lysek DA, Perez DR, Guntert P, Wüthrich K. Prion<br />
protein NMR structures of chickens, turtles, <strong>and</strong> frogs. Proc Natl<br />
Acad Sci USA 102: 651–655, 2005.<br />
89. Canello T, Engelstein R, Moshel O, Xanthopoulos K, Juanes<br />
ME, Langeveld J, Sklaviadis T, Gasset M, Gabizon R. Methionine<br />
sulfoxides on PrPSc: a prion-specific covalent signature. Biochemistry<br />
47: 8866–8873, 2008.<br />
90. Carp RI. Transmission of scrapie by oral route: effect of gingival<br />
scarification. Lancet 1: 170–171, 1982.<br />
91. Cashman NR, Loertscher R, Nalbantoglu J, Shaw I, Kascsak<br />
RJ, Bolton DC, Bendheim PE. Cellular isoform of the scrapie<br />
agent protein participates in lymphocyte activation. Cell 61: 185–<br />
192, 1990.<br />
92. Castilla J, Gonzalez-Romero D, Saa P, Morales R, De Castro<br />
J, Soto C. Crossing the species barrier by PrP(Sc) replication in<br />
vitro generates unique infectious prions. Cell 134: 757–768, 2008.<br />
93. Castilla J, Morales R, Saa P, Barria M, Gambetti P, Soto C.<br />
Cell-free propagation of prion strains. EMBO J 27: 2557–2565, 2008.<br />
94. Castilla J, Saa P, Hetz C, Soto C. In vitro generation of infectious<br />
scrapie prions. Cell 121: 195–206, 2005.<br />
95. Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med<br />
11: 982–985, 2005.<br />
96. Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a grip on<br />
prions: oligomers, amyloids, <strong>and</strong> pathological membrane interactions.<br />
Annu Rev Biochem 78: 177–204, 2009.<br />
97. Caughey B, Horiuchi M, Demaimay R, Raymond GJ. Assays of<br />
protease-resistant prion protein <strong>and</strong> its formation. Methods Enzymol<br />
309: 122–133, 1999.<br />
98. Caughey B, Race RE. Potent inhibition of scrapie-associated PrP<br />
accumulation by congo red. J Neurochem 59: 768–771, 1992.<br />
99. Caughey B, Raymond GJ. The scrapie-associated form of PrP is<br />
made from a cell surface precursor that is both protease- <strong>and</strong><br />
phospholipase-sensitive. J Biol Chem 266: 18217–18223, 1991.<br />
100. Caughey B, Raymond GJ. Sulfated polyanion inhibition of<br />
scrapie-associated PrP accumulation in cultured cells. J Virol 67:<br />
643–650, 1993.<br />
101. Caughey B, Raymond GJ, Bessen RA. Strain-dependent differences<br />
in beta-sheet conformations of abnormal prion protein.<br />
J Biol Chem 273: 32230–32235, 1998.<br />
Physiol Rev VOL 89 OCTOBER 2009 www.prv.org<br />
102. Caughey B, Raymond LD, Raymond GJ, Maxson L, Silveira J,<br />
Baron GS. Inhibition of protease-resistant prion protein accumulation<br />
in vitro by curcumin. J Virol 77: 5499–5502, 2003.<br />
103. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey<br />
WS. Secondary structure analysis of the scrapie-associated protein<br />
PrP 27–30 in water by infrared spectroscopy. Biochemistry 30: 7672–<br />
7680, 1991.<br />
104. Caughey WS, Raymond LD, Horiuchi M, Caughey B. Inhibition<br />
of protease-resistant prion protein formation by porphyrins <strong>and</strong><br />
phthalocyanines. Proc Natl Acad Sci USA 95: 12117–12122, 1998.<br />
105. Ch<strong>and</strong>ler RL. Encephalopathy in mice produced by inoculation<br />
with scrapie brain material. Lancet 1: 1378–1379, 1961.<br />
106. Chazot G, Broussolle E, Lapras C, Blättler T, Aguzzi A, Kopp<br />
N. New variant of Creutzfeldt-Jakob disease in a 26-year-old French<br />
man. Lancet 347: 1181, 1996.<br />
107. Chesebro B, Race R, Wehrly K, Nishio J, Bloom M, Lechner D,<br />
Bergstrom S, Robbins K, Mayer L, Keith JM. Identification of<br />
scrapie prion protein-specific mRNA in scrapie-infected <strong>and</strong> uninfected<br />
brain. Nature 315: 331–333, 1985.<br />
108. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C,<br />
LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey<br />
B, Masliah E, Oldstone M. Anchorless prion protein results in<br />
infectious amyloid disease without clinical scrapie. Science 308:<br />
1435–1439, 2005.<br />
109. Chiesa R, Piccardo P, Ghetti B, Harris DA. Neurological illness<br />
in transgenic mice expressing a prion protein with an insertional<br />
mutation. Neuron 21: 1339–1351, 1998.<br />
110. Chiti F, Dobson CM. <strong>Protein</strong> misfolding, functional amyloid, <strong>and</strong><br />
human disease. Annu Rev Biochem 75: 333–366, 2006.<br />
111. Clarke MC, Kimberlin RH. Pathogenesis of mouse scrapie: distribution<br />
of agent in the pulp <strong>and</strong> stroma of infected spleens. Vet<br />
Microbiol 9: 215–225, 1984.<br />
112. Clarke MC, Millson GC. Infection of a cell line of mouse L<br />
fibroblasts with scrapie agent. Nature 261: 144–145, 1976.<br />
113. Clouscard C, Beaudry P, Elsen JM, Milan D, Dussaucy M,<br />
Bounneau C, Schelcher F, Chatelain J, Launay JM, Laplanche<br />
JL. Different allelic effects of the codons 136 <strong>and</strong> 171 of the prion<br />
protein gene in sheep with natural scrapie. J Gen Virol 76: 2097–<br />
2101, 1995.<br />
114. Cohen AS, Shirahama T, Skinner M. Electron microscopy of<br />
amyloid. In: Electron Microscopy of <strong>Protein</strong>s, edited by Harris JR.<br />
New York: Academic, 1982, p. 165–206.<br />
115. Cole S, Kimberlin RH. Pathogenesis of mouse scrapie: dynamics<br />
of vacuolation in brain <strong>and</strong> spinal cord after intraperitoneal infection.<br />
Neuropathol Appl Neurobiol 11: 213–227, 1985.<br />
116. Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg<br />
Psychiatry 76: 906–919, 2005.<br />
117. Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to<br />
iatrogenic Creutzfeldt-Jakob disease. Lancet 337: 1441–1442, 1991.<br />
118. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular<br />
analysis of prion strain variation <strong>and</strong> the aetiology of “new variant”<br />
CJD. Nature 383: 685–690, 1996.<br />
119. Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas<br />
DJ, Alpers MP. Kuru in the 21st century–an acquired human prion<br />
disease with very long incubation periods. Lancet 367: 2068–2074,<br />
2006.<br />
120. Collinge J, Whittington MA, Sidle KC, Smith CJ, Palmer MS,<br />
Clarke AR, Jefferys JG. Prion protein is necessary for normal<br />
synaptic function. Nature 370: 295–297, 1994.<br />
121. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters<br />
CL. Quinacrine does not prolong survival in a murine Creutzfeldt-<br />
Jakob disease model. Ann Neurol 52: 503–506, 2002.<br />
122. Colombo G, Meli M, Morra G, Gabizon R, Gasset M. Methionine<br />
sulfoxides on prion protein Helix-3 switch on the alpha-fold<br />
destabilization required for conversion. PLoS ONE 4: e4296, 2009.<br />
123. Cooper E. Quinacrine in possible or probable CJD: it is blinded<br />
investigators, not patients, who must be in equipoise over treatment.<br />
BMJ 324: 239, 2002.<br />
124. Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related<br />
to prealbumin in familial amyloidotic polyneuropathy. Proc Natl<br />
Acad Sci USA 75: 4499–4503, 1978.<br />
125. Cousens SN, Harries Jones R, Knight R, Will RG, Smith PG,<br />
Matthews WB. Geographical distribution of cases of Creutzfeldt-